Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China
Author:
Funder
National Natural Science Foundation of China
Publisher
Frontiers Media SA
Subject
Endocrinology, Diabetes and Metabolism
Reference23 articles.
1. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013;Wang;JAMA,2017
2. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030;Whiting;Diabetes Res Clin Pract,2011
3. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetologia,2015
4. Evidence-based practice guideline for the treatment for diabetes in Japan 2013;Tajima;Diabetol Int.,2015
5. Methods to enhance delivery of prandial insulin and basal-prandial insulin;Garber;Diabetes Obes Metabol.,2013
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double‐blind, placebo‐controlled, parallel study;Diabetes, Obesity and Metabolism;2023-03-23
2. Rate of glycaemic control and associated factors in patients with type 2 diabetes mellitus treated with insulin-based therapy at selected hospitals in Northwest Ethiopia: a multicentre cross-sectional study;BMJ Open;2022-09
3. Glycemic control in newly insulin-initiated patients with type 2 diabetes mellitus: A retrospective follow-up study at a university hospital in Ethiopia;PLOS ONE;2022-05-26
4. Effects of basal and premixed insulin on glycemic control in type 2 diabetes patients based on multicenter prospective real‐world data;Journal of Diabetes;2022-01-13
5. Efficacy and safety of linagliptin as add‐on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled trial;Diabetes, Obesity and Metabolism;2020-11-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3